{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T11:06:50Z","timestamp":1772536010352,"version":"3.50.1"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To identify the opportunity of targeting patients with elevated lipoprotein(a) [Lp(a)] in patients with peripheral arterial disease (PAD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Lp(a) plays a causal role in atherosclerotic cardiovascular disease. Cohort studies demonstrate that elevated Lp(a) levels independently associate with an increased risk of developing PAD. Patients with manifest PAD have a high residual cardiovascular risk, despite use of traditional lipid lowering. The current approach to treatment of patients with high Lp(a) levels involves intensification of management of conventional cardiovascular risk factors and consideration of use of aspirin. In recent years, therapeutic programs have developed injectable RNA targeted agents and a small molecule Lp(a) assembly disrupter that are well tolerated and produce effective Lp(a) lowering. Many of these agents are being evaluated in large cardiovascular outcomes trials. Advances have also looked to develop gene\/base editing and epigenetic treatments to lower Lp(a).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>These studies demonstrate that Lp(a) plays an important role in cardiovascular disease, including PAD. However, it remains to be determined if more effective Lp(a) lowering will translate to cardiovascular benefit. If this does prove to be the case, integration of Lp(a) testing and therapeutics has the potential to transform clinical outcomes in people living with PAD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000001002","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T15:00:13Z","timestamp":1753282813000},"page":"232-237","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic lowering of lipoprotein(a): implications for improving outcomes in patients with peripheral arterial disease"],"prefix":"10.1097","volume":"36","author":[{"given":"Stephen J.","family":"Nicholls","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"R1-20250904","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"R2-20250904","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"R3-20250904","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"R4-20250904","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"R5-20250904","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018\u200aAHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R6-20250904","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019\u200aESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"R7-20250904","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jacc.2005.07.006","article-title":"The forgotten majority: unfinished business in cardiovascular risk reduction","volume":"46","author":"Libby","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R8-20250904","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Diseases","year":"2020","journal-title":"Lancet"},{"key":"R9-20250904","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1161\/CIRCULATIONAHA.108.191171","article-title":"Atherosclerotic Peripheral Vascular Disease Symposium II: nomenclature for vascular diseases","volume":"118","author":"Hiatt","year":"2008","journal-title":"Circulation"},{"key":"R10-20250904","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/0003319707302494","article-title":"The prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patients","volume":"58","author":"Poredos","year":"2007","journal-title":"Angiology"},{"key":"R11-20250904","doi-asserted-by":"crossref","first-page":"N1","DOI":"10.1177\/1358863X17701592","article-title":"2016\u200aAHA\/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: executive summary","volume":"22","author":"Writing Committee","year":"2017","journal-title":"Vasc Med"},{"key":"R12-20250904","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S2213-8587(18)30290-0","article-title":"Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial","volume":"6","author":"Bonaca","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R13-20250904","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"R14-20250904","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jvs.2006.12.054","article-title":"Heart Protection Study Collaborative G: randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions","volume":"45","year":"2007","journal-title":"J Vasc Surg"},{"key":"R15-20250904","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jacc.2019.03.013","article-title":"Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES Trial","volume":"74","author":"Jukema","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R16-20250904","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial","volume":"141","author":"Schwartz","year":"2020","journal-title":"Circulation"},{"key":"R17-20250904","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"R18-20250904","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J Lipid Res"},{"key":"R19-20250904","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in man\u2014the Lp system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"key":"R20-20250904","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"key":"R21-20250904","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/eurheartj\/ehae652","article-title":"Within-person stability of lipoprotein(a) concentration","volume":"46","author":"Ghouse","year":"2025","journal-title":"Eur Heart J"},{"key":"R22-20250904","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jacc.2024.10.081","article-title":"Intraindividual variability in serial lipoprotein(a) concentrations among placebo-treated patients in the OCEAN(a)-DOSE Trial","volume":"85","author":"Gaba","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"R23-20250904","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J Intern Med"},{"key":"R24-20250904","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1161\/ATVBAHA.108.179697","article-title":"Oxidized low-density lipoprotein and atherosclerosis","volume":"30","author":"Steinberg","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R25-20250904","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis","volume":"83","author":"Bjornson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"R26-20250904","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"key":"R27-20250904","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1194\/jlr.P030890","article-title":"Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions","volume":"53","author":"van Dijk","year":"2012","journal-title":"J Lipid Res"},{"key":"R28-20250904","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.jacc.2014.01.055","article-title":"Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans","volume":"63","author":"Ravandi","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R29-20250904","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/jamacardio.2024.1874","article-title":"Lipoprotein(a) and long-term plaque progression, low-density plaque, and pericoronary inflammation","volume":"9","author":"Nurmohamed","year":"2024","journal-title":"JAMA Cardiol"},{"key":"R30-20250904","doi-asserted-by":"crossref","first-page":"e002060","DOI":"10.1136\/openhrt-2022-002060","article-title":"Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease","volume":"9","author":"Nissen","year":"2022","journal-title":"Open Heart"},{"key":"R31-20250904","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/ng.2480","article-title":"Large-scale association analysis identifies new risk loci for coronary artery disease","volume":"45","author":"Consortium","year":"2013","journal-title":"Nat Genet"},{"key":"R32-20250904","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"R33-20250904","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R34-20250904","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"key":"R35-20250904","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"R36-20250904","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering Therapies: a Mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"R37-20250904","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Emerging Risk Factors","year":"2009","journal-title":"JAMA"},{"issue":"(1\u20132)","key":"R38-20250904","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0021-9150(81)90103-9","article-title":"Lipoprotein Lp(a) and the risk for myocardial infarction","volume":"38","author":"Kostner","year":"1981","journal-title":"Atherosclerosis"},{"key":"R39-20250904","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"R40-20250904","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1194\/jlr.P066258","article-title":"Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study","volume":"57","author":"Verbeek","year":"2016","journal-title":"J Lipid Res"},{"key":"R41-20250904","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jacc.2023.12.031","article-title":"Lipoprotein(a) and major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease","volume":"83","author":"Berman","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"R42-20250904","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.04.015","article-title":"Lipoprotein(a) and cardiovascular and valvular diseases: a genetic epidemiological perspective","volume":"349","author":"Arsenault","year":"2022","journal-title":"Atherosclerosis"},{"key":"R43-20250904","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2022.06.019","article-title":"Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC review topic of the week","volume":"80","author":"Tsimikas","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R44-20250904","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R45-20250904","first-page":"16889","article-title":"Intraindividual variability of lipoprotein(a) in the middle-aged population: the impact of smoking","volume":"134","author":"Golab","year":"2024","journal-title":"Pol Arch Intern Med"},{"key":"R46-20250904","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1161\/CIRCULATIONAHA.124.070361","article-title":"Prevalence of lipoprotein(a) testing in a contemporary cohort","volume":"151","author":"Bansal","year":"2025","journal-title":"Circulation"},{"key":"R47-20250904","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11883-024-01187-6","article-title":"Lipoprotein(a): from causality to treatment","volume":"26","author":"Kronenberg","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"R48-20250904","doi-asserted-by":"crossref","first-page":"100651","DOI":"10.1016\/j.ajpc.2024.100651","article-title":"High lipoprotein(a): actionable strategies for risk assessment and mitigation","volume":"18","author":"Reyes-Soffer","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"R49-20250904","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","article-title":"Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes","volume":"80","author":"Lacaze","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R50-20250904","doi-asserted-by":"crossref","first-page":"e033562","DOI":"10.1161\/JAHA.123.033562","article-title":"Aspirin and cardiovascular risk in individuals with elevated lipoprotein(a): the Multi-Ethnic Study of Atherosclerosis","volume":"13","author":"Bhatia","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"R51-20250904","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2016.01.005","article-title":"Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a)","volume":"10","author":"Yeang","year":"2016","journal-title":"J Clin Lipidol"},{"key":"R52-20250904","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"key":"R53-20250904","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur Heart J"},{"key":"R54-20250904","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-lowering by 50\u200amg\/dL (105\u200anmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R55-20250904","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"R56-20250904","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"R57-20250904","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of Lipoprotein(a) lowering with Pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"key":"R58-20250904","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"R59-20250904","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jacc.2024.05.058","article-title":"The off-treatment effects of olpasiran on lipoprotein(a) lowering: OCEAN(a)-dose extension period results","volume":"84","author":"O\u2019Donoghue","year":"2024","journal-title":"J Amer Coll Cardiol"},{"key":"R60-20250904","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"R61-20250904","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran - a long-duration small interfering RNA targeting lipoprotein(a)","volume":"392","author":"Nissen","year":"2025","journal-title":"N Engl J Med"},{"key":"R62-20250904","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s41586-024-07387-z","article-title":"Discovery of potent small-molecule inhibitors of lipoprotein(a) formation","volume":"629","author":"Diaz","year":"2024","journal-title":"Nature"},{"key":"R63-20250904","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jama.2023.16503","article-title":"Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial","volume":"330","author":"Nicholls","year":"2023","journal-title":"JAMA"},{"key":"R64-20250904","doi-asserted-by":"crossref","first-page":"100723","DOI":"10.1016\/j.jlr.2024.100723","article-title":"Measuring Lp(a) particles with a novel isoform-insensitive immunoassay illustrates efficacy of muvalaplin","volume":"66","author":"Swearingen","year":"2025","journal-title":"J Lipid Res"},{"key":"R65-20250904","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2024.24017","article-title":"Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial","volume":"333","author":"Nicholls","year":"2025","journal-title":"JAMA"},{"key":"R66-20250904","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2024.5433","article-title":"Olpasiran, oxidized phospholipids, and systemic inflammatory biomarkers: results from the OCEAN(a)-DOSE trial","author":"Rosenson","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"(Suppl 1)","key":"R67-20250904","first-page":"A17013","article-title":"CTX320: an investigational in vivo CRISPR-based therapy efficiently and durably reduces lipoprotein (a) levels in nonhuman primates after a single dose","volume":"148","author":"Morrow","year":"2023","journal-title":"Circ"},{"key":"R68-20250904","first-page":"2497","article-title":"2024\u200aACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Writing Committee","year":"2024","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000001002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T10:02:20Z","timestamp":1756980140000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000001002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000001002","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]}}}